Listen to this episode of Longevity by Design on Apple Podcasts, Spotify, and YouTube.
On this episode of Longevity by Design, Dr. Gil Blander speaks with Dr. Michael Ringel, COO of Life Biosciences, about the science of aging and longevity. Michael discusses how evolution influences lifespan and why aging occurs. He explains the trade-off between resource allocation for reproduction versus maintenance and repair within the body. Caloric restriction and its effects on lifespan are explored through an evolutionary lens.
Michael highlights the challenges and breakthroughs in longevity research. He touches upon the role of genetics and pharmaceuticals in manipulating lifespan and healthspan. He points to the Pacific rockfish as an example of varying lifespans within a closely related group of species, demonstrating the genetic component of aging. He also notes the impact of Cell reprogramming, referencing a study on how specific Cell reprogramming can regenerate optic nerves.
The conversation shifts to the business of longevity, where Michael discusses the increased interest and investments from big pharma and billionaires. He examines the economic benefits of extending healthspan, citing a potential value of $300 trillion from a 10-year healthspan extension in the US alone. Michael and Gil also explore the importance of lifestyle choices for healthy aging, emphasizing diet, exercise, sleep, stress management, and social connections.
💡 Name: Dr. Michael Ringel
💡What they do: COO
💡Company: Life Biosciences
💡Noteworthy: Biotechnology COO bridging science and business for longevity breakthroughs.
💡 Where to find them: LinkedIn
Episode highlights:
[00:00:56] Meet Dr. Michael Ringel
[00:02:30] Journey to Becoming a Scientist
[00:04:26] Interest in Longevity and Aging
[00:07:59] Evolution and Aging
[00:21:04] Caloric Restriction and Lifespan
[00:25:07] InsideTracker: Personalized Healthspan Optimization
[00:26:02] Pharma's Role in Aging Research
[00:37:32] Understanding Causality in Medical Research
[00:38:09] Challenges of Observational Studies
[00:39:40] Experimental Studies and the TAME Trial
[00:40:21] Pharmaceutical Incentives and Metformin
[00:40:56] Exploring Rapalogs and Patent Issues
[00:43:39] Hallmarks of Aging and Future Prospects
[00:45:59] Investment in Aging Research
[00:52:35] Economic and Social Impacts of Longevity
[01:02:30] Practical Tips for Extending Lifespan
Aging: Not a Bug, but a Feature
Aging isn't a biological malfunction but a result of evolutionary pressures. Organisms prioritize reproduction and growth over maintenance and repair because passing on genes is evolution's primary goal. This trade-off means resources are allocated to ensure the continuation of the species, even at the expense of individual longevity. Understanding this evolutionary context reframes how we approach aging research and interventions. It suggests that extending lifespan isn't about fixing a broken system, but about rebalancing resource allocation to favor both reproduction and long-term health.
Unlocking Longevity's Potential Through Science & Business
The intersection of scientific advancements and business investment holds immense potential for extending both lifespan and healthspan. Biotech companies developing innovative therapies, like partial epigenetic reprogramming, are crucial for translating research into practical applications. Simultaneously, big pharma's involvement is essential for large-scale clinical trials and commercialization, making these therapies accessible to a wider population. Increased investment from both sectors, coupled with a growing awareness of aging's economic impact, is driving a rapid expansion of the longevity field.
Lifestyle Choices: Your Most Powerful Longevity Tool
While advanced therapies hold promise, lifestyle choices remain your most immediate and effective tool for improving health and longevity. Prioritizing a balanced, plant-based diet, regular exercise, adequate sleep, stress management, and fostering strong social connections can significantly extend your healthy years. These habits, often referred to as the "Holy Trinity" of healthy aging, offer significant benefits individually and have a synergistic effect when combined. These aren't just anecdotal recommendations; studies show individuals practicing these habits experience longer, healthier lives.
The Illusion of Infinite Resources and the Reality of Lifespan Limits
Michael challenges the common misconception that aging is simply due to accumulating mutations. He argues that resource limitations play a crucial evolutionary role in determining lifespan. Organisms must balance resource allocation between growth, reproduction, and maintenance. This trade-off results in varying lifespans across species, with those facing higher extrinsic mortality (like predation) having shorter lifespans.
"Lifespan is selected for, and the key reason is that energy and other resources are not infinite. They have a budget in terms of how resources are allocated, and growth and reproduction versus maintenance repair is kind of a key trade-off."
The Promise and Challenges of Partial Reprogramming
Michael discusses partial epigenetic reprogramming as a potential game-changer in longevity research. This technology aims to reverse the aging process by tapping into the biological mechanisms that allow us to create younger offspring from older selves. The challenge lies in decoupling the age reversal from the loss of cellular identity, ensuring that cells retain their specialized functions while becoming younger. This approach offers the potential for true rejuvenation and has shown therapeutic benefits in animal models of age-related diseases.
"It taps into the same biology that allows us to make babies when we’re old. The offspring will be born as babies from our old selves. The question is, can we do that without losing the identity of the cell."
The Business of Longevity: From Biotech to Big Pharma
The longevity field is witnessing increased interest and investment, not only from biotech companies but also from big pharma. Michael emphasizes the importance of promising clinical trial results for attracting pharma investment. The development of therapies that address multiple age-related diseases simultaneously offers an attractive risk profile for pharma, leading to broader pipelines and increased access to treatments for patients.
"Assets that have been brought to at least Phase 2 of clinical trials, where you've got some efficacy data, become the same story that they have for any other kind of drug candidate, seems to work. We're excited about it."
Optimizing for Healthspan, Not Just Lifespan
While extending lifespan is a key focus of longevity research, optimizing healthspan, or the number of healthy years lived, is equally, if not more, important. Michael highlights the power of lifestyle interventions – diet, exercise, sleep, stress management, and social connections – to significantly improve healthspan. He references a VA study identifying eight habits associated with a longer lifespan, demonstrating the accessible and impactful nature of these interventions.
"Don't ignore the healthspan effect. So, maybe lifespan is only a couple of years, but if you can get a decade or even two decades of better health and productivity and happiness."
For science-backed ways to live a healthier longer life, download InsideTracker's Top 5 biomarkers for longevity eBook at insidetracker.com/podcast
Similar Longevity By Design episodes we think you would love: